Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company’s board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron, and Orexo.
In August 2022, Pneumagen initiated a Phase 2 challenge study of its Neumifil multivalent carbohydrate binding module (mCBM) nasal spray. The company is developing Neumifil for protection against respiratory viral infections, including influenza, RSV, and COVID-19. Pneumagen raised £3.8 million in January 2022 to support the Phase 2 trial and GMP manufacturing of Neumifil and announced positive results from a Phase 1 trial of the nasal spray in May 2022.
Noble commented, “I am honored to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data. I look forward to working closely with the company’s impressive team and driving forward the strategy to deliver such a potentially important new product for patients at high-risk of viral-induced exacerbations caused by respiratory viruses.”
Pneumagen CEO Douglas Thomson said, “We are very pleased to welcome James to the board who brings a wealth of strategic, corporate and financial expertise to Pneumagen. James’ considerable experience will be invaluable as we progress our Phase 2 clinical trial with our lead asset, Neumifil. We look forward to leveraging James’ global network and deep knowledge of the biotech sector as we continue our commitment to deliver an important new therapy to vulnerable patients at risk from viral RTIs.”
Read the Pneumagen press release.
